Redx Pharma (LON:REDX) Share Price Passes Below 50-Day Moving Average of $15.52

Redx Pharma Plc (LON:REDX)’s stock price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 15.52 ($0.19) and traded as low as GBX 8.02 ($0.10). Redx Pharma shares last traded at GBX 10 ($0.12), with a volume of 469,387 shares traded.

Redx Pharma Price Performance

The company has a debt-to-equity ratio of 527.00, a quick ratio of 1.93 and a current ratio of 1.11. The firm has a fifty day simple moving average of GBX 15.31 and a two-hundred day simple moving average of GBX 20.42. The firm has a market cap of £35.01 million, a PE ratio of -90.00 and a beta of -0.53.

Insiders Place Their Bets

In related news, insider Lisa Anson bought 399,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of GBX 8 ($0.10) per share, with a total value of £31,920 ($39,426.88). Corporate insiders own 18.23% of the company’s stock.

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.